Net revenue grew 5.6% year-over-year to BRL 585 million, while adjusted EBITDA and net income declined due to higher costs and a non-cash impairment from the CSN divestment. Leverage rose to 2.2x, and expansion projects remain on track.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.